SPRC SciSparc Ltd.
Price Chart
Executive Summary
SciSparc's subsidiary NeuroThera Labs received conditional TSX Venture Exchange approval for its acquisition of ~54% of CliniQuantum Ltd., a private Israeli quantum simulation company. The deal consideration is ~56.6M NeuroThera shares valued at ~$9.46M based on the 20-day VWAP. The closing date was extended to June 1, 2026, and the amendment established a $0.05 floor price for earn-out shares and lock-up arrangements for selling shareholders. This is a procedural milestone in a previously disclosed transaction with no new financial data for SciSparc itself.
Actionable Insight
Monitor the June 1, 2026 closing deadline and final TSX acceptance. The deal is small relative to SciSparc's $6M market cap and occurs at the subsidiary level, so limited direct SPRC price impact. Watch for any subsequent dilution or cash needs at the NeuroThera level that could affect SciSparc's consolidated position.
Key Facts
- NeuroThera Labs received conditional TSX Venture Exchange approval for the acquisition of ~54% of CliniQuantum Ltd.
- Consideration is 56,600,000 NeuroThera common shares, valued at approximately $9,459,954.20 based on the 20-day VWAP.
- Closing date extended from April 30, 2026 to June 1, 2026.
- Amendment established a $0.05 floor price for any earn-out share issuances and requires lock-up arrangements for selling shareholders.
- CliniQuantum's material asset is an exclusive license to a single US provisional patent application for quantum simulation in clinical trials.
- SciSparc's market cap is ~$6M; the transaction occurs at the NeuroThera (TSXV: NTLX) subsidiary level.
Financial Impact
Transaction valued at ~$9.46M in NeuroThera shares; SciSparc's direct financials unchanged in this filing.
Risk Factors
- Transaction may not close if conditions (Israeli tax ruling, final TSX acceptance) are not met by June 1, 2026.
- CliniQuantum's sole material asset is a single provisional patent application — no guarantee of commercial value.
- Issuance of 56.6M NeuroThera shares could dilute SciSparc's effective ownership in its subsidiary.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-062431 |
| Document: ea0292562-6k_scisparc.htm | 0001213900-26-062431 |
| Document: ea029256201ex99-1.htm | 0001213900-26-062431 |
| Document: 0001213900-26-062431-index-headers.html | 0001213900-26-062431 |
| Document: 0001213900-26-062431-index.html | 0001213900-26-062431 |
| Document: 0001213900-26-062431.txt | 0001213900-26-062431 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
6-K
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.71% | $11.44 (−0.87%) |
|
Jun 4, 2026
1d ago
|
Press Release
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.71% | $11.44 (−0.87%) |
|
May 29, 2026
7d ago
|
6-K
| $9.81 $10.59 | ▲ +7.95% | ▲ +7.68% | $11.44 (+16.62%) |
|
May 28, 2026
8d ago
|
Press Release
| $10.55 $9.81 | ▼ −7.01% | ▼ −7.26% | $11.44 (+8.44%) |
|
Mar 16, 2026
11w ago
|
Press Release
| $4.32 $4.62 | ▲ +6.94% | ▲ +6.67% | $11.44 (+164.81%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.73 $4.36 | ▼ −7.82% | ▼ −7.22% | $11.44 (+141.86%) |
|
Mar 10, 2026
12w ago
|
Press Release
| $4.02 $3.85 | ▼ −4.23% | ▼ −4.12% | $11.44 (+184.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access